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Summary
Background Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are 
associated with accelerated bone loss. We assessed eﬀ ectiveness of oral risedronate for prevention of reduction in 
bone mineral density (BMD) after 3 years of follow-up in a subset of patients in the IBIS-II trial.
Methods The double-blind IBIS-II trial recruited 3864 healthy, postmenopausal women at increased risk of breast cancer 
and randomly allocated them oral anastrozole (1 mg/day) or matched placebo. 1410 (36%) postmenopausal women were 
then enrolled in a bone substudy and stratiﬁ ed at baseline according to their lowest baseline T score at spine or femoral 
neck (stratum I: T score at least –1·0; stratum II: T score at least –2·5 but less than –1·0; stratum III: T score less than 
–2·5 but greater than –4·0). Women in stratum I were monitored only; women in stratum III were all given risedronate 
(35 mg/week). Women in stratum II were randomly assigned (1:1) to risedronate (35 mg/week) or matched placebo by 
use of a block randomisation schedule via a web-based programme. The primary outcome of this per-protocol analysis 
(done with all women with a baseline and 3 year DXA assessment) was the eﬀ ect of risedronate versus placebo for 
osteopenic women in stratum II randomly allocated to anastrozole (1 mg/day). Secondary outcomes included eﬀ ect of 
anastrozole (1 mg/day) on BMD in women not receiving risedronate (strata I and II) and in osteoporotic women who 
were all treated with risedronate (stratum III). The trial is ongoing, but no longer recruiting. This trial is registered, 
number ISRCTN31488319.
Findings Between Feb 2, 2003, and Sept 30, 2010, 150 (58%) of 260 women in stratum II who had been randomly 
allocated to anastrozole and either risedronate or placebo had baseline and 3 year assessments. At the lumbar spine, 
3 year mean BMD change for the 77 women receiving anastrozole/risedronate was 1·1% (95% CI 0·2 to 2·1) versus 
–2·6% (–4·0 to –1·3) for the 73 women receiving anastrozole/placebo (p<0·0001). For the total hip, 3 year mean BMD 
change for women receiving anastrozole/risedronate was –0·7% (–1·6 to 0·2) versus –3·5% (–4·6 to –2·3) for women 
receiving anastrozole/placebo (p=0·0001). 652 (65%) of 1008 women in strata I and II who were not randomly allocated 
to risedronate had both baseline and 3 year assessments. Women not receiving risedronate in stratum I and II who 
received anastrozole (310 women) had a signiﬁ cant BMD decrease after 3 years of follow-up compared with women 
who received placebo (342 women) at the lumbar spine (–4·0% [–4·5 to –3·4] vs –1·2% [–1·7 to –0·7], p<0·0001) and 
total hip (–4·0% [–4·4 to –3·6] vs –1·8% [–2·1 to –1·4], p<0·0001). 106 (79%) of 149 women in stratum III had a 
baseline and a 3 year assessment. The 46 women allocated to anastrozole had a modest BMD increase of 1·2% (–0·1 
to 2·6) at the spine compared with a 3·9% (2·6 to 5·2) increase for the 60 women allocated to placebo (p=0·006). For 
the total hip, a small 0·3% (–0·9 to 1·5) increase was noted for women allocated anastrozole compared with a 1·5% 
(0·5 to 2·5) increase for women allocated placebo, but the diﬀ erence was not signiﬁ cant (p=0·12). The most common 
adverse event reported was arthralgia (stratum I: 94 placebo and 114 anastrozole; stratum II: 39 placebo/placebo, 
25 placebo/risedronate, 34 anastrozole/placebo, and 34 anastrozole/risedronate; stratum III: 21 placebo/risedronate, 
17 anastrozole/risedronate). Other adverse events included hot ﬂ ushes, alopecia, abdominal pain, and back pain.
Interpretation Risedronate counterbalances the eﬀ ect of anastrozole-induced bone loss in osteopenic and osteoporotic 
women and might be oﬀ ered in combination with anastrozole treatment to provide an improved risk–beneﬁ t proﬁ le.
Funding Cancer Research UK (C569/A5032), National Health and Medical Research Council Australia (GNT300755, 
GNT569213), Sanoﬁ -Aventis, and AstraZeneca.
Introduction
Oestrogen has a major role in the regulation of skeletal 
homoeostasis, and therefore physiological decreases in 
oestrogen concentrations place postmenopausal women 
at high risk of osteoporosis (low bone mineral density 
[BMD]). Reduction in BMD in the ﬁ rst 7 years after the 
menopause is 1–3% per year at the spine and 1–2% per 
year at the hip.1 Bone loss can be treated or prevented 
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with bisphosphonates, which increase BMD by inhibition 
of osteoclast-mediated bone resorption.2,3
This risk of BMD loss, and therefore fractures, is 
aggravated in postmenopausal women with breast cancer 
who are given an aromatase inhibitor as part of their 
treatment.4,5 Aromatase inhibitors suppress oestrogen 
concentrations in postmenopausal women by inhibition of 
the conversion of androgens to oestrogens by the 
aromatase enzyme in soft tissues, especially fat. Studies 
from large adjuvant trials show signiﬁ cant BMD decreases 
and higher fracture rates in women receiving aromatase 
inhibitors compared with women on tamoxifen.6–9 In the 
ATAC trial, anastrozole signiﬁ cantly decreased BMD at the 
lumbar spine (6·1%) and total hip (7·2%) after 5 years of 
follow-up, whereas a signiﬁ cant increase in BMD was 
noted with tamoxifen.6 Similarly, the results from the 
BIG 1–98 conﬁ rmed a signiﬁ cant BMD loss and an 
increased fracture rate with letrozole compared with 
tamoxifen.10 Most of the studies investigating the eﬀ ect of 
aromatase inhibitors on bone density have been done in 
postmenopausal women with early breast cancer receiving 
adjuvant tamoxifen as a comparison group. Tamoxifen has 
a beneﬁ cial eﬀ ect on BMD and it is therefore diﬃ  cult to 
determine the true eﬀ ect of aromatase inhibitors on BMD.
Two large prevention trials11,12 comparing an aromatase 
inhibitor with placebo in postmenopausal women at 
high risk of development of breast cancer have recently 
reported their main ﬁ ndings. The MAP.3 trial,11 which 
investigated exemestane for the prevention of breast 
cancer, reported a signiﬁ cant BMD loss at the lumbar 
spine and total hip with exemestane compared with 
placebo after 2 years of follow-up.13 Overall, no increases 
in fractures with exemestane were reported, but the 
follow-up of 35 months was too short to make a ﬁ rm 
conclusion about this endpoint. The IBIS-II trial12 
compared anastrozole with placebo in postmenopausal 
women at high risk of development of breast cancer and 
noted a signiﬁ cant reduction in breast cancer with 
anastrozole. Here we report the ﬁ rst results of a per-
protocol analysis of the placebo-controlled IBIS-II bone 
substudy, which assesses the eﬀ ect of 3 years of 
risedronate on BMD in postmenopausal women with 
healthy bone density, osteopenia, or osteoporosis.
Methods
Study design and participants
The IBIS-II trial recruited 3864 healthy, postmenopausal 
women at increased risk of breast cancer and randomly 
allocated them to receive either 1 mg/day oral 
anastrozole or matching placebo.12 Eligible women were 
oﬀ ered the opportunity to enter a bone substudy. 
Eligibility criteria for the main IBIS-II study have been 
summarised in detail elsewhere.12 In brief, 
postmenopausal women aged 40–70 years were 
recruited from 44 centres from seven countries. Study 
sites were those in IBIS-II that consented to do dual 
energy x-ray absorptiometry (DXA) scans as part of the 
follow-up trial (appendix) and deemed postmenopausal 
when they were aged 60 years or older; had had a 
bilateral oophorectomy; were younger than 60 years, but 
had a uterus and amenorrhoea for at least 12 months; or 
were younger than 60 years, had no uterus, and had a 
concentration of follicle stimulating hormone of greater 
than 30 IU/L. Exclusion criteria for the main trial 
included premenopausal status, any previous diagnosis 
of invasive cancers, present use of selective oestrogen 
receptor modulators for more than 6 months, intention 
to continue with hormone-replacement therapy, 
evidence of severe osteoporosis (T score less than –4·0), 
and lack of physiological or psychological ﬁ tness. 
Women in the bone substudy were enrolled and 
stratiﬁ ed into three groups according to the lowest 
baseline T score at either femoral neck or lumbar spine. 
Women with healthy T score (at least –1·0) were entered 
into stratum I. Women who were osteopenic (T score at 
least –2·5 but less than –1·0) were entered into 
stratum II. Finally, osteoporotic women with a T score 
of less than –2·5 but greater than –4·0 or those with one 
to two low trauma fragility fractures (as assessed by 
spinal radiographs) were entered into stratum III. 
Spinal radiographs within the 2 years before 
randomisation were used to rule out low trauma 
fractures. Women were advised to take vitamin D and 
calcium supplements, but no speciﬁ c doses were 
speciﬁ ed or required by study protocol. Exclusion 
criteria for the bone substudy included previous bilateral 
hip fractures or any type of metabolic bone disease. 
Furthermore, women who had regularly taken 
medication aﬀ ecting bone metabolism within the past 
12 months before study entry were also excluded. 
Finally, women who had a T score of less than –4·0 and 
those with more than two low trauma fractures, were 
excluded from the bone substudy and referred for 
further management. The trial was approved by the UK 
North West Multicentre Research Ethics Committee and 
was done in accordance with the Declaration of 
Helsinki, under the principles of good clinical practice. 
Participants provided written informed consent.
Randomisation and masking
Women in stratum II were randomly assigned to receive 
risedronate (35 mg/week) or matched placebo. 
Randomisation was done with randomly chosen blocks 
of size six, eight, or ten to maintain balance and was not 
stratiﬁ ed. The non-consecutive allocation sequence was 
generated by the IBIS-II programmer before the study 
started who also assigned the interventions to all women. 
All IBIS-II personnel, participants, and clinicians were 
masked to treatment allocation and only the IBIS-II trial 
statistician (IS) had access to unmasked data.
Procedures
All women entering the main IBIS-II study were required 
to have a DXA scan before study entry for stratiﬁ cation 
See Online for appendix
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and exclusion purposes. In the bone substudy, BMD was 
further assessed by follow-up DXA scans at the lumbar 
spine and total hip at 12, 36, and 60 months. Women who 
had a BMD loss of 6% or more at the 12 month visit were 
required to have a safety DXA scan at 24 months of 
follow-up. Similarly, women with a BMD loss of more 
than 10% at 36 months had a safety scan at 48 months, 
and those with a BMD loss of more than 16% at the 
60 months visit had an interval scan at 72 months.
We calculated T scores with either the Lunar14 or 
Hologic15 manufacturer’s reference ranges for the lumbar 
spine (L1 to L4) and the National Health and Nutrition 
Examination Survey (NHANES) III reference range for 
the femoral neck region.16 All baseline and follow-up 
DXA scans were reviewed centrally by two clinical 
scientists with expertise in bone densitometry (GMB and 
RP) to ensure quality assurance. Regular phantom 
reports from all participating centres were reviewed and 
investigators were requested to use the same DXA 
machine whenever possible throughout the study.
Women in stratum I were monitored only. Women in 
stratum II of the bone substudy were randomly allocated 
to receive either 35 mg/week oral risedronate or 
matching placebo for 5 years. All women in stratum III 
(osteoporotic women) received oral risedronate 
(35 mg/week) for 5 years. Women in strata II and III 
were advised to take their allocated risedronate or 
matching placebo in an upright position upon waking in 
the morning on an empty stomach, and not to consume 
anything apart from water within the next 30 min to 
minimise risk of inactivation of the drug or oesophageal 
irritation. Women were allowed to have a dose reduction 
(ie, alternate weeks) or go on treatment holiday from 
risedronate if they developed severe adverse events 
potentially related to the trial medication.
For biomarker analyses, a 10 mL urine sample from the 
second void was collected at baseline and 12 months. We 
measured N-telopeptide of type I collagen (NTx) levels 
with the Ortho Clinical Diagnostics automated immuno-
assay (High Wycombe, UK). The interassay coeﬃ  cient of 
variation for NTx was 6·4%. NTx was expressed as a ratio 
to creatinine (nmol bone collagen equivalent:mmol 
creatinine) and the interassay coeﬃ  cient of variation for 
creatinine was 1·8%.
Outcomes
The primary objective of this analysis was to compare the 
eﬀ ect of risedronate versus placebo on BMD between 
baseline and 3 years at both the lumbar spine and total 
hip in women taking anastrozole in stratum II. Secondary 
endpoints included the eﬀ ect of anastrozole versus 
placebo at the total hip and lumbar spine on BMD in 
women in stratum I and stratum II who had not been 
randomly allocated to risedronate at 3 years; the eﬀ ect of 
Figure 1: IBIS-II bone substudy trial proﬁ le
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383 allocated 
 placebo
9 breast cancer
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anastrozole versus placebo on BMD at the total hip and 
lumbar spine in women in stratum III at 3 years; and 
changes from baseline in biochemical markers (NTx to 
creatinine ratio) between baseline and 12 months of 
follow-up in all three strata.
Statistical analysis
All analyses were done on a per-protocol basis, in which 
women were included only if a baseline and 36 month 
DXA scan were available. In stratum II, our power 
calculations were designed to detect a diﬀ erence of 1·6% 
between risedronate and placebo in women randomly 
allocated to anastrozole with 90% power. Power 
calculations for stratum I aimed to detect a diﬀ erence of 
1·4% between anastrozole and placebo with 90% power. 
Similar assumptions were made for women in 
stratum III, in which all women received risedronate.
Initial calculations suggested that we needed 
500 women per strata. Recruiting osteoporotic women 
was diﬃ  cult (number not achieved) whereas recruiting 
women with healthy bone was unproblematic. We thus 
entered postmenopausal women into the bone substudy 
until we had recruited 500 women into stratum II, which 
was needed to achieve power for primary objective. This 
analysis focuses on BMD changes between baseline and 
36 months. Women ceased participation in the bone 
substudy if one of the following events occurred: 
withdrawal from main study, development of breast 
cancer, death, and if rapid bone loss occurred. These 
women were excluded from this analysis. We assessed 
normal distribution of all continuous variables with 
histograms and diagnostic distribution plots. All main 
results are expressed as percentage mean BMD changes 
at the total hip or lumbar spine between baseline and 
36 months with corresponding 95% CIs. BMD changes 
and diﬀ erences between treatment groups were assessed 
using t tests for two independent samples with 
corresponding 95% CI. For the NTx to creatinine ratio 
analysis, we report the estimated median (95% CI) 
percentage change from baseline to 12 months. 
We report two-sided p values, based on normal 
approximation, and all CIs at the 95% level. Analyses 
were done with STATA version 12.1.
This trial is registered, number ISRCTN31488319.
Role of the funding source
Sanoﬁ -Aventis and AstraZeneca provided anastrozole 
and matched placebo. The sponsor or funding bodies of 
this study had no role in study design, collection of data 
or material, data analysis, interpretation of the data, or 
writing of the manuscript. IS had full access to all raw 
data. IS, JC, and RE had ﬁ nal responsibility to submit the 
report for publication.
Results
Between Feb 2, 2003, and Sept 30, 2010, we enrolled 
1410 postmenopausal women into the bone substudy 
with a median follow-up of 3·0 years (IQR 2·95–3·09; 
ﬁ gure 1). 761 (54%) women were stratiﬁ ed into stratum I, 
500 (35%) into stratum II, and 149 (11%) into stratum III. 
Baseline and 36 month DXA scans were available for 
903 (64%) women, who were included in this analysis 
(ﬁ gure 1). No further DXA scans were done for women 
who withdrew from the main IBIS-II study (199 in 
stratum I, 127 in stratum II, 32 in stratum III), developed 
breast cancer (28 in stratum I, 12 in stratum II, four in 
stratum III), or died (nine in stratum I, four in stratum II, 
three in stratum III; no deaths were treatment related), 
and these women were excluded from the analysis 
(ﬁ gure 1). 256 (72%) of the 358 women who withdrew 
from the main IBIS-II study did so before the 12 month 
follow-up visit (126 in stratum I, 112 in stratum II, 18 in 
stratum III) and therefore were excluded from this 
analysis. 55 women had a BMD decrease of more than 
6% at the 12 month follow-up (36 in stratum I, 17 in 
stratum II, and two in stratum III). 13 of these women 
did not continue with the trial medication and were 
therefore excluded from this analysis (eight in stratum I, 
ﬁ ve in stratum II; ﬁ gure 1). Only 76 (5%) of 1410 women 
withdrew from the bone substudy without ﬁ rst 
withdrawing from the main study (23 in stratum I, 49 in 
stratum II, and four in stratum III).
Stratum I Stratum II Stratum III
Placebo (n=257) Anastrozole 
(n=237)
Placebo/placebo 
(n=85)
Placebo/
risedronate 
(n=68)
Anastrozole/
placebo (n=73)
Anastrozole/
risedronate 
(n=77)
Placebo/
risedronate 
(n=60)
Anastrozole/
risedronate 
(n=46)
Age (years) 58·7 (54·1–62·3) 58·4 (54·8–61·9) 59·4 (56·7–63·5) 60·8 (57·4–63·8) 60·2 (55·4–64·9) 60·0 (56·1–64·8) 61·9 (58·5–64·1) 59·3 (54·4–62·9)
Body-mass index (kg/m²) 28·7 (25·8–32·2) 28·6 (25·3–32·6) 27·1 (23·7–30·7) 26·4 (24·5–29·3) 26·3 (24·0–30·6) 26·4 (23·7–29·1) 26·3 (24·0–28·7) 25·4 (22·9–28·3)
Previous HRT use 129 (50%) 104 (44%) 35 (41%) 33 (45%) 31 (46%) 38 (49%) 23 (38%) 22 (48%)
Never smokers 156 (61%) 124 (52%) 54 (64%) 47 (64%) 39 (57%) 44 (57%) 37 (62%) 25 (54%)
Hysterectomy 80 (31%) 80 (34%) 21 (25%) 21 (29%) 21 (31%) 18 (23%) 18 (30%) 12 (26%)
Oophorectomy 47 (18%) 28 (12%) 8 (9%) 12 (16%) 11 (16%) 14 (18%) 3 (5%) 5 (11%)
Baseline T score –0·22 (0·89) –0·27 (0·82) –1·40 (0·55) –1·66 (0·53) –1·44 (0·59) –1·64 (0·62) –2·64 (0·55) –2·70 (0·56)
Data are median (IQR), n (%), or mean (SD). DXA=dual energy x-ray absorptiometry. HRT=hormone-replacement therapy.
Table 1: Baseline characteristics for all postmenopausal women with a baseline and 36 month DXA scan available
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Baseline characteristics for women with available 
baseline and 36 month DXA scans are shown in table 1. 
The baseline characteristics between women all receiving 
anastrozole and randomly allocated to risedronate versus 
placebo were evenly distributed and we noted no major 
diﬀ erences (table 1). Similarly, for women in stratum I 
and II not receiving risedronate but randomly allocated 
to anastrozole versus placebo, we noted no substantial 
diﬀ erences in baseline characteristics. Women in 
stratum III who were randomly allocated to receive 
placebo were older than were those randomly allocated to 
anastrozole (p=0·043; table 1). All other comparisons in 
this stratum were not substantially diﬀ erent between 
treatment groups. We compared baseline demographics 
and BMD for women included in this analysis with those 
who were excluded. No major diﬀ erences between these 
two groups were noted for all baseline characteristics 
(data not shown).
In the analysis of women in stratum II who had all 
received anastrozole and either risedronate or placebo, 
150 (58%) of 260 women had baseline and 36 month 
DXA scans available for analysis (77 anastrozole/
risedronate vs 73 anastrozole/placebo). Women randomly 
allocated to anastrozole and receiving risedronate had a 
mean BMD increase of 1·1% (95% CI 0·2 to 2·1) at the 
lumbar spine after 36 months’ follow-up compared with 
a mean decrease of –2·6% (–4·0 to –1·3) in those not 
receiving risedronate (p<0·0001; ﬁ gure 2, appendix). We 
noted a linear decrease in BMD at the lumbar spine and 
total hip for women randomly allocated to anastrozole 
over 36 months’ follow-up. Although BMD for the total 
hip decreased by only –0·7% (95% CI –1·6 to 0·2) for 
women on anastrozole and risedronate after 36 months’ 
follow-up, the diﬀ erence was signiﬁ cant compared with 
women on only anastrozole, who had a decrease of 
–3·5% (–4·6 to –2·3; p=0·0001; ﬁ gure 2, appendix).
In the analysis of women in stratum I and II who were 
not randomly allocated to risedronate and received only 
anastrozole or placebo, 652 (65%) of 1008 had baseline 
and 36 month DXA scans. We noted a linear decrease in 
mean BMD for all groups between baseline and 
36 months, irrespective of main randomisation (ﬁ gure 2). 
However, we noted a signiﬁ cantly larger decrease at the 
lumbar spine or total hip for women randomly allocated 
to anastrozole compared with placebo (lumbar spine: 
–4·0% [95% CI –4·5 to –3·4] for anastrozole vs –1·2% 
[–1·7 to –0·7] for placebo, p<0·0001; total hip: –4·0% 
[–4·4 to –3·6] for anastrozole vs –1·8% [–2·1 to –1·4] for 
placebo; p=0·0001; ﬁ gure 2, appendix).
In the analysis of women in stratum III who had all 
received risedronate and either anastrozole or placebo, 
106 (71%) of 149 women had baseline and 36 month 
DXA scans. We noted the largest increase in mean 
percentage BMD at the lumbar spine for women 
randomly allocated to placebo (3·9% increase [95% CI 
2·6 to 5·2]) whereas we noted a smaller increase for 
women randomly allocated to anastrozole (1·2% 
increase [–0·09 to 2·6]; p=0·006; ﬁ gure 2, appendix). We 
noted a rapid increase in BMD with risedronate within 
the ﬁ rst 12 months of follow-up at the lumbar spine 
(ﬁ gure 2). For the total hip, we noted an increase in 
mean percentage BMD in both treatment groups, with a 
Figure 2: Bone mineral density changes at lumbar spine and total hip at each follow-up visit
(A–B) Women in stratum II receiving anastrozole who were randomly allocated to either risedronate or placebo. 
(C–D) Women in stratum I or II not receiving risedronate who were randomly allocated to either anastrozole or 
placebo. (E–F) Women in stratum III (all receiving risedronate) who were randomly allocated to either anastrozole 
or placebo. Error bars show 95% CIs.
M
ea
n  
BM
D 
ch
an
ge
 (%
)
77
73
77
73
77
73
Anastrozole/risedronate
Anastrozole/placebo
–4·0%
–1·2%
–1·8%
–4·0%
1·2%
3·9%
1·5%
0·3%
–1
–2
–3
–4
–5
0
1
3
2
4
5
Baseline 12 months 36 months
–2·6%
1·1%
–3·5%
–0·7%
A Lumbar spine
Anastrozole/risedronate
Anastrozole/placebo
77
73
77
73
77
73
Baseline 12 months 36 months
B Total hip
M
ea
n  
BM
D 
ch
an
ge
 (%
)
M
ea
n  
BM
D 
ch
an
ge
 (%
)
310
342
310
342
310
342
Anastrozole
Placebo
–5·0
0
0·5
–0·5
–1·0
–1·5
–2·0
–2·5
–3·0
–3·5
–4·0
–4·5
Baseline 12 months 36 months
310
342
310
342
310
342
Baseline 12 months 36 months
C Lumbar spine D Total hip
46
60
46
60
46
60
Anastrozole/risedronate
Placebo/risedronate
1·0
0·5
0
–0·5
–1·0
1·5
2·0
3·5
3·0
4·5
5·0
Baseline 12 months 36 months
46
60
46
60
46
60
Baseline 12 months 36 months
E Lumbar spine
2·5
4·0
F Total hip
Anastrozole
Placebo
Placebo/risedronate
Anastrozole/risedronate
Articles
www.thelancet.com/oncology   Vol 15   December 2014 1465
smaller increase noted in women randomly allocated to 
anastrozole (anastrozole: 0·3% increase [95% CI –0·9 to 
1·5] vs placebo: 1·5% increase [0·5 to 2·5]; p=0·12; 
ﬁ gure 2, appendix).
Second void morning urine samples were analysed for 
NTx and creatinine in 866 women in the bone substudy. 
627 (72%) women had a sample available at baseline and 
12 months and these samples were the basis for this 
analysis (table 2). In stratum I, we noted a signiﬁ cant 
median increase of almost 9% after 12 months in women 
randomly allocated to anastrozole, but no diﬀ erence with 
placebo (table 2). The diﬀ erence between treatment 
groups for the yearly change in NTx to creatinine ratio 
was signiﬁ cant (p<0·0001; table 2). Women in stratum II 
who were randomly allocated to anastrozole but not to 
risedronate had a signiﬁ cant median increase in NTx to 
creatinine ratio of almost 12% by 12 months of follow-up 
whereas those randomly allocated to placebo did not 
Stratum I Stratum II Stratum III
Placebo 
(n=147)
Anastrozole 
(n=142)
p value Placebo/
placebo (n=70)
Placebo/
risedronate 
(n=58)
Anastrozole/
placebo (n=69)
Anastrozole/
risedronate 
(n=67)
p value Placebo/
risedronate 
(n=43)
Anastrozole/
risedronate 
(n=31)
p value
Baseline 37·3
(34·7 to 39·8)
39·1
(35·8 to 42·3)
0·3 43·0
(36·4 to 49·7)
43·0
(35·3 to 50·6)
43·1
(34·8 to 51·3)
44·3
(38·7 to 50·0)
0·8 50·7
(43·8 to 57·6)
52·2
(45·1 to 59·4)
0·8
12 months 34·9
(31·5 to 38·3)
49·5
(45·3 to 53·6)
<0·0001 44·1
(39·4 to 48·9)
24·6
(17·6 to 31·6)
55·6
(49·7 to 61·6)
33·7
(28·3 to 39·1)
<0·0001 23·5
(16·5 to 30·5)
32·7
(23·1 to 42·3)
0·1
Median 
change, %*
–1·9%
(–4·8 to 1·0)
8·9%
(4·4 to 13·4)
<0·0001 –1·8%
(–6·7 to 3·2)
–16·1%
(–18·6 to –13·6)
11·7%
(6·2 to 17·1)
–13·0%
(–17·5 to –8·5)
<0·0001 –25·4%
(–35·6 to –15·2)
–19·0%
(–26·1 to –11·9)
0·3
p value† 0·5 <0·0001 ·· 0·3 <0·0001 0·0013 0·0002 ·· <0·0001 0·0002 ··
 Data are % (95% CI), unless otherwise stated. *Median of individual diﬀ erences between baseline and 12 months.†Diﬀ erence between baseline and 12 months.
Table 2: Median baseline, 12 month, and median percentage changes for N-telopeptide to creatinine ratios
Stratum I Stratum II Stratum III
Placebo 
(n=257)
Anastrozole 
(n=237)
Placebo/
placebo 
(n=85)
Placebo/
risedronate 
(n=68)
Anastrozole/
placebo 
(n=73)
Anastrozole/
risedronate 
(n=77)
Placebo/
risedronate 
(n=60)
Anastrozole/
risedronate 
(n=46)
Arthralgia 94 (37%) 114 (48%) 39 (46%) 25 (37%) 34 (47%) 34 (44%) 21 (35%) 17 (37%)
Hot ﬂ ush 24 (9%) 22 (9%) 7 (8%) 3 (4%) 5 (7%) 7 (9%) 5 (8%) 5 (11%)
Alopecia 13 (5%) 11 (5%) 2 (2%) 5 (7%) 3 (4%) 1 (1%) 1 (2%) 3 (7%)
Abdominal pain 6 (2%) 6 (3%) 5 (6%) 1 (1%) 1 (1%) 2 (3%) 4 (7%) 1 (2%)
Essential hypertension 6 (2%) 2 (1%) 0 1 (1%) 1 (1%) 0 0 0
Cataract 5 (2%) 2 (1%) 1 (1%) 1 (1%) 1 (1%) 0 1 (2%) 0
Arthritis 5 (2%) 2 (1%) 1 (1%) 1 (1%) 1 (1%) 0 1 (2%) 1 (2%)
Amnesia 1 (<1%) 3 (1%) 1 (1%) 0 0 1 (1%) 3 (5%) 3 (7%)
Anxiety 4 (2%) 2 (1%) 1 (1%) 0 0 0 0 0
Back pain 4 (2%) 8 (3%) 3 (4%) 1 (1%) 0 0 2 (3%) 2 (4%)
Abdominal distension 2 (1%) 0 1 (1%) 0 1 (1%) 1 (1%) 1 (2%) 1 (2%)
Depression 2 (1%) 0 0 0 0 0 0 0
Acute sinusitis 3 (1%) 0 0 0 0 0 0 0
Constipation 3 (1%) 0 0 0 1 (1%) 0 0 0
Cystitis 3 (1%) 0 0 0 2 (3%) 0 0 1 (2%)
Dyspepsia 2 (1%) 1 (<1%) 0 0 1 (1%) 0 0 1 (2%)
Acne 1 (<1%) 0 0 0 0 0 0 0
Angina pectoris 2 (1%) 2 (1%) 0 0 0 0 1 (2%) 0
Balance disorder 1 (<1%) 1 (<1%) 0 0 0 0 0 1 (2%)
Emotional disorder 0 1 (<1%) 0 0 1 (1%) 0 0 1 (2%)
Goitre 1 (<1%) 0 0 0 0 0 0 0
Gynaecological events 1 (<1%) 1 (<1%) 0 1 (1%) 0 1 (1%) 1 (2%) 1 (2%)
Total 183 (71%) 178 (75%) 61 (72%) 39 (57%) 52 (71%) 47 (61%) 41 (68%) 38 (83%)
See appendix for a breakdown of adverse events by severity.
Table 3: Adverse events (any grade)
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show a signiﬁ cant change in this marker (table 2). By 
contrast, women who were randomly allocated to receive 
risedronate in stratum II had signiﬁ cant median 
decreases in NTx to creatinine ratios after 12 months of 
follow-up, irrespective of main treatment allocation 
(table 2). The diﬀ erences in NTx to creatinine ratio 
between randomisation groups were signiﬁ cant after 
12 months of follow-up in stratum II (p<0·0001). We 
noted decreases in NTx to creatinine concentrations were 
observed for both treatment groups for women in 
stratum III, but the diﬀ erence was not signiﬁ cant 
(table 2).
639 (45%) of 1410 women in the IBIS-II bone substudy 
had adverse events (table 3). Incidence did not diﬀ er 
between treatment allocations within each stratum. No 
serious adverse events, such as osteonecrosis of the jaw 
or serious gastrointestinal problems, were reported after 
3 years of follow-up with risedronate. Only 85 women 
had a treatment interruption from risedronate between 
baseline and 36 months (median 3 weeks [IQR 2–5]; 
65 women in stratum II and 20 women in stratum III). 
By 36 months of follow-up, two women in stratum I (one 
anastrozole, one placebo) and 23 women in stratum II 
(six placebo/placebo, two placebo/risedronate, ten 
anastrozole/placebo, and ﬁ ve anastrozole/risedronate) 
developed osteoporosis and subsequently stopped trial 
medication to start open-label bisphosphonates. Overall, 
128 fractures were reported by 109 women in the bone 
substudy (44 women in stratum I, 51 women in stratum 
II, and 14 women in stratum III). 57 (8%) of 711 women 
randomly allocated to anastrozole reported at least one 
fracture compared with 52 (7%) of 699 in the placebo 
group. The incidence rate for fractures in the anastrozole 
arm was 13·7 per 1000 woman-years compared with 
12·6 per 1000 woman-years in the placebo arm (p=0·70). 
The number of fractures is too small at present to report 
stratum speciﬁ c data, and further follow-up is needed.
Discussion
The mean percentage BMD loss in women on placebo in 
our study is similar to that reported in the overall 
population of similar age.17 The IBIS-II results conﬁ rm 
that 3 years of anastrozole decreases BMD at the lumbar 
spine or total hip in healthy postmenopausal women, as 
previously reported (panel).13 More importantly, our 
results show that risedronate counterbalances BMD loss 
induced by anastrozole in women with osteopenia or 
osteoporosis. Similar ﬁ ndings have been reported by two 
smaller studies in patients with breast cancer.18,19 Both 
trials showed that the addition of a bisphosphonate 
normalises bone turnover in such patients receiving 
anastrozole after 2 years. Longer follow-up is needed to 
assess the fracture risk in healthy postmenopausal 
women receiving anastrozole. Risedronate was well 
tolerated and no serious adverse events, such as 
osteonecrosis of the jaw or serious gastrointestinal 
problems, were reported after 3 years of follow-up.
Bisphosphonates are well established drugs for the 
prevention of bone loss and reduction of fractures in 
postmenopausal women and men with osteoporosis.2,20,21 
Oral and intravenous bisphosphonates signiﬁ cantly 
reduce the incidence of vertebral and non-vertebral 
fractures.22 In the adjuvant setting, anastrozole, letrozole, 
and exemestane have all been assessed in postmenopausal 
women with early breast cancer.23–26 These trials have all 
shown signiﬁ cant BMD loss with these drugs, but have 
in common that the comparator was tamoxifen, which 
has been shown to have a beneﬁ cial eﬀ ect on bone.6,7,9 
Zoledronic acid can prevent BMD loss induced by 
letrozole or anastrozole in postmenopausal women with 
breast cancer.27–29 A small study assessing risedronate in 
women with breast cancer receiving anastrozole showed 
that this drug was eﬀ ective in preventing anastrozole 
induced bone loss.30 In a large review, the European 
guidelines31 for the management of aromatase inhibitor 
induced bone loss concluded that the use of 
bisphosphonates for treatment of osteoporosis in 
postmenopausal women with breast cancer is safe and 
that these drugs are eﬀ ective in the prevention of BMD 
loss because of endocrine therapy.
In the preventive setting, the bone substudy of the 
MAP.3 trial,13 which compared exemestane with placebo, 
recently reported their results on bone density changes 
in a subgroup of women. Their primary endpoint was 
the comparison of percentage change in total volumetric 
BMD at the distal radius between baseline and 2 years of 
follow-up by quantitative CT. However, they also reported 
on BMD changes at the lumbar spine and total hip by 
DXA as a secondary objective, and reported that women 
Panel: Research in context
Systematic review
We searched PubMed for randomly allocated trials in the preventive setting published in 
English before May 30, 2014, that investigated a bisphosphonate in women at high risk 
of breast cancer treated with an aromatase inhibitor. We used the search terms “breast 
cancer”, “prevention”, “high risk”, “aromatase inhibitor”, and “bisphosphonate”. We 
identiﬁ ed no other breast cancer prevention trials investigating the eﬀ ect of a 
bisphosphonate in combination with an aromatase inhibitor in postmenopausal women 
at high risk of development of the disease. However, we identiﬁ ed several trials in the 
adjuvant setting. We identiﬁ ed one other prevention trial13 in postmenopausal women 
comparing exemestane with placebo that reported on bone mineral density changes in 
this study group, but did not investigate the use of a bisphosphonate.
Interpretation
Results from our trial provide the ﬁ rst evidence that risedronate prevents anastrozole-
induced bone mineral density loss in postmenopausal women at high risk of 
development of breast cancer with osteopenia or osteoporosis. Risedronate was well 
tolerated and no serious adverse events associated with this drug were reported. Because 
aromatase inhibitors have emerged as a treatment option for the reduction of breast 
cancer risk for postmenopausal women, the concomitant use of a bisphosphonate is 
inevitable in this setting. However, long-term follow-up is required for the assessment of 
risedronate on fracture risk and for overall bone mineral density changes over the course 
of 5 years of anastrozole use.
Articles
www.thelancet.com/oncology   Vol 15   December 2014 1467
randomly allocated to exemestane had a signiﬁ cant 
decrease in BMD at all sites compared with placebo after 
2 years of follow-up. The MAP.3 trial did not assess the 
use of a bisphosphonate in women receiving exemestane 
and therefore a direct comparison between the two trials 
in that respect is not possible.
Anastrozole resulted in signiﬁ cant increases in bone 
turnover whereas women on placebo showed little change 
after 12 months in those with healthy bone or osteopenic 
women and not receiving risedronate. Other studies, in 
the adjuvant setting, have also shown that aromatase 
inhibitors are associated with higher concentrations of 
bone resorption makers.7,8,32 By contrast, those women 
who were randomly allocated to risedronate in stratum II 
or osteoporotic women (stratum III) receiving risedronate 
showed signiﬁ cant decreases in NTx to creatinine ratio by 
12 months of follow-up.
Strengths of our analysis include an overall large 
sample size (1410 women), with a large proportion of 
women with osteopenia, long follow-up of 3 years, and a 
population that came from a large prevention trial with 
excellent clinical records. Furthermore, this trial is the 
ﬁ rst time that a bisphosphonate has been compared with 
a placebo in healthy postmenopausal woman at risk of 
development of breast cancer who are taking anastrozole 
as a preventive drug. This analysis reports on the 3 year 
BMD changes, but we will be able to present results after 
5 years of treatment and are in the process of obtaining a 
DXA scan 2 years after treatment cessation to investigate 
whether BMD loss induced by anastrozole is regained.
Limitations of our study include the incomplete set of 
BMD data at 36 months (903 [64%] of 1410 women). 
Speciﬁ cally for our primary objective, the number of 
women included in the analysis was small, but 
nevertheless we detected signiﬁ cant diﬀ erences between 
the treatment groups. This ﬁ nding is mainly attributable 
to withdrawal from the main IBIS-II study in the ﬁ rst 
3 years and therefore our results might not be 
representative for the whole study population. However, 
only 5·4% of women withdrew from the bone substudy 
without ﬁ rst leaving the main study. A few participants 
were lost to follow-up because centres changed their DXA 
scanner to a diﬀ erent manufacturer. Wherever possible, 
this problem was mitigated by arranging for the women 
to be scanned on a similar machine at a diﬀ erent hospital. 
A further limitation of this study is the insuﬃ  cient follow-
up length for fracture risk assessment. DXA is the 
standard clinical technique for skeletal assessment of 
BMD changes and fracture risk, but does not take into 
account bone structure and micro architecture of the 
bone. Bone structure, especially cortical structure of the 
bone, probably plays an important part in determination 
of bone strength,13,33,34 but assessment of these bone 
structure changes was not possible.
To our knowledge, this analysis was the ﬁ rst to 
investigate the eﬀ ect of risedronate on anastrozole-
induced bone loss in healthy postmenopausal women in 
a placebo-controlled trial. Our ﬁ ndings conﬁ rm BMD 
loss induced by anastrozole in healthy postmenopausal 
women in the preventive setting. However, we also 
showed that risedronate counterbalances the eﬀ ect of 
anastrozole-induced bone loss in osteopenic and 
osteoporotic women. Longer follow-up is needed to 
assess the risk of fracture with anastrozole in healthy 
postmenopausal women. Nevertheless, careful 
monitoring of bone density by DXA scans and the use of 
a bisphosphonate can control BMD loss induced by 
anastrozole in the preventive setting.
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